sorafenib has been researched along with Acute Lymphoid Leukemia in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Y; Chen, S; Hong, Y; Sun, A; Tian, X; Xiang, X; Yu, Y; Zeng, Z; Zhang, L | 1 |
| Aymerich, M; Bataller, A; Camós, M; Colomer, D; Díaz-Beyá, M; Esteve, J; Garrote, M; López-Guerra, M; Oliver-Caldés, A; Vega-García, N | 1 |
| Kagechika, H; Kurosu, T; Miura, O; Ohki, M; Wu, N | 1 |
| Baker, SD; Carducci, MA; Cho, E; Gore, SD; Karp, JE; Levis, MJ; McDevitt, M; Pratz, KW; Rudek, MA; Smith, BD; Stine, A; Wright, JJ; Zhao, M | 1 |
| Amoroso, F; Boldt, S; Dahlhaus, M; Etro, D; Freund, M; Fuellen, G; Glass, A; Junghanss, C; Lange, S; Neri, LM; Ruck, S; Sawitzky, M; Schult, C; Wolkenhauer, O | 1 |
| Andreeff, M; Borthakur, G; Cortes, JE; Faderl, S; Kantarjian, H; Konopleva, M; Mathews, S; Ravandi, F; Verstovsek, S; Wright, JJ; Zhang, W | 1 |
| Thomas, X | 1 |
1 review(s) available for sorafenib and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
[Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzenesulfonates; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2007 |
1 trial(s) available for sorafenib and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyridines; Remission Induction; Salvage Therapy; Sorafenib; Survival Rate; Young Adult | 2011 |
5 other study(ies) available for sorafenib and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Identification of immune subtypes of Ph-neg B-ALL with ferroptosis related genes and the potential implementation of Sorafenib.
Topics: Adolescent; Adult; Antineoplastic Agents; Apoptosis; Child; Cluster Analysis; Female; Ferroptosis; Humans; Leukemia, B-Cell; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Risk Factors; RNA-Seq; Sorafenib; Treatment Outcome; Tumor Microenvironment; Unsupervised Machine Learning; Young Adult | 2021 |
Early T-cell precursor lymphoblastic leukaemia: response to FLAG-IDA and high-dose cytarabine with sorafenib after initial refractoriness.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sorafenib; Treatment Outcome; Vidarabine | 2019 |
Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Topics: Acetophenones; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzenesulfonates; Benzopyrans; Biphenyl Compounds; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Mutation; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyridines; Pyrimidines; Sorafenib; Sulfonamides | 2009 |
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regulated MAP Kinases; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib | 2010 |
The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Benzenesulfonates; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Humans; Jurkat Cells; Niacinamide; Phenylurea Compounds; Phosphorylation; Poly(ADP-ribose) Polymerases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Sorafenib; T-Lymphocytes | 2010 |